Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 2/20 | 0.58 |
| ▸ | YARS1 | P54577 | 2/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | NPY4R | P50391 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.56 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9419220 | 1.00 | SLC7A5 (0.61) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL10789173 | 1.00 | SLC7A5 (0.61) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL678159 | 1.00 | SLC7A5 (0.61) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL30839475 | 1.00 | SLC7A5 (0.61) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL29657676 | 1.00 | SLC7A5 (0.61) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL31025673 | 0.97 | SLC7A5 (0.65) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL1574161 | 0.97 | SLC7A5 (0.65) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL30439955 | 0.97 | SLC7A5 (0.65) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL27653020 | 0.97 | SLC7A5 (0.65) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL1574158 | 0.97 | SLC7A5 (0.65) | SLC7A5MMEYARS1ACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940791-B2 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2789341-A2 | O-acetylated amino acids as anti-platelet agents and nutritional supplements | Chandran, V. Ravi (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140200256-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-20110312890-A1 | ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110275713-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| US-8003683-B2 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1957066-A2 | ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS | Chandran, V. Ravi (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007059047-A2 | ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS | CHANDRAN V RAVI (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070112060-A1 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200256-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | PLTP, GP6, PDGFA | SLC7A5 500/4885MME 2430/4885YARS1 3232/4885 |
| US-20110312890-A1 | ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS | PLTP, GP6, PDGFA | SLC7A5 500/4885MME 2430/4885YARS1 3232/4885 |
| US-20070112060-A1 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | PLTP, GP6, PDGFA | SLC7A5 500/4885MME 2430/4885YARS1 3232/4885 |
| US-20110275713-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | PLTP, GP6, PDGFA | SLC7A5 500/4885MME 2430/4885YARS1 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.